Triasima Portfolio Management inc. Buys New Holdings in Cencora, Inc. $COR

Triasima Portfolio Management inc. bought a new stake in Cencora, Inc. (NYSE:COR) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,361 shares of the company’s stock, valued at approximately $1,050,000.

Several other institutional investors have also recently added to or reduced their stakes in COR. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares in the last quarter. Vermillion & White Wealth Management Group LLC boosted its stake in Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after buying an additional 43 shares during the last quarter. Caldwell Trust Co purchased a new stake in Cencora in the second quarter valued at approximately $46,000. Salomon & Ludwin LLC increased its stake in Cencora by 638.1% during the third quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock worth $47,000 after acquiring an additional 134 shares during the last quarter. Finally, Capital A Wealth Management LLC raised its stake in shares of Cencora by 3,975.0% during the second quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after purchasing an additional 159 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the transaction, the chief executive officer owned 65,746 shares of the company’s stock, valued at $24,105,113.44. This trade represents a 7.19% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 15,220 shares of company stock valued at $5,343,561. Corporate insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on COR. Robert W. Baird set a $415.00 price objective on Cencora in a research report on Tuesday, January 13th. Barclays initiated coverage on Cencora in a report on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective for the company. Mizuho lifted their price target on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, Wells Fargo & Company lifted their price target on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average target price of $381.42.

Cencora Price Performance

Shares of COR stock opened at $355.86 on Tuesday. The company has a market cap of $69.03 billion, a P/E ratio of 44.86, a P/E/G ratio of 1.69 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The business has a fifty day simple moving average of $349.45 and a 200 day simple moving average of $320.73. Cencora, Inc. has a twelve month low of $237.71 and a twelve month high of $377.54.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period in the previous year, the firm posted $3.34 EPS. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is currently 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.